pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1231 |
Genomic Coordinates | chr1: 201808611 - 201808702 |
Synonyms | MIRN1231, hsa-mir-1231, MIR1231 |
Description | Homo sapiens miR-1231 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1231 | |||||||||||||||
Sequence | 5| GUGUCUGGGCGGACAGCUGC |24 | |||||||||||||||
Evidence | Experimental | |||||||||||||||
Experiments | Cloned | DRVs in miRNA |
|
|||||||||||||
SNPs in miRNA |
|
|||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | HSPB6 | ||||||||||||||||||||
Synonyms | HEL55, Hsp20, PPP1R91 | ||||||||||||||||||||
Description | heat shock protein family B (small) member 6 | ||||||||||||||||||||
Transcript | NM_144617 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on HSPB6 | |||||||||||||||||||||
3'UTR of HSPB6 (miRNA target sites are highlighted) |
>HSPB6|NM_144617|3'UTR 1 GAGGGGGCTGGGCCGCGCCCGCACCCCGGGAGCCTCCTCAGGCTCCCTCTATTAAAGCCGATCTGACTCCGCCCAGCCAG81 ATGTCCCGAGTGCGCCAAGGACTGTCCTCTCACCCACTCCTGGATTCTGCCCTGACCTCCATCCTGGACACTGCCTTGAT 161 AACATAGACCCTTCCACTGACACCCTCGCTCTCACACCCCCTCCAGCTTTCCGACCCCACACCGACAACTCCCCGGCTTC 241 CAGACCCTACCAGCACTACCCTAACCCTCAGCCGACAGTCTCAGCCCCACCGACCCACTTTCTTGGCATATAGCCCCACT 321 TAAGACCCCTCCTCTACTTCCTTCTGAGTCCTCTACAAAGACATCCGGGTACTACATTTCCATCCCTTCCCTATTTTGAC 401 ACCAAATTATGGTGTAGACAGCCCTCCCCCAACCCCAGGCCAGTCAGGCACAATCCCCCCACCCCCCAAACGTCCTGGAC 481 TGCACAGACCTCCCACTCCAGACCATCCAGGCCTGGTTCCCAAGACCCGATCCTTCCCCTGCAACCAGACAGTCTACAAC 561 TGCCCCCTCCAGCCCATTTTCTGCCGTGAAACCCCAGCCAGCCACACCAGACTCTGGAACCCTTTTTCGACTGCCCCAAC 641 TCTTGGACACCAGGCCAACTAGAACACCCAACACCAAACTGTACAGACTCTCCCACCCCAACCTCCCCAGACTCTGCACG 721 GATGTCCTAGGCCCCCTCCCCAACTCTAACCAGACCCCATCCCCCTAAGTCCCTTTGTCTTGACCCCCAAGTCTTCAACC 801 AGATATCCTCGGCAACCCACCTCCCACCCTCCTCCTCTTCTCCTTCAAGACCCAACTGAGCACCCGCTCTGATTCCCCAC 881 AGCCTTTCTCCCTGCCACCACTCCCTTAGTCTTTCCCAGGCTTACTCTCCCAATAAATGTGCTAGAGCTCTGCCAAAAAA 961 AAAAAAAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HEK293 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM545213. RNA binding protein: AGO2. Condition:Control
... - Hafner M; Landthaler M; Burger L; Khorshid et al., 2010, Cell. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
CLIP-seq Support 1 for dataset GSM545213 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | HEK293 / Control |
Location of target site | ENST00000592984.1 | 3UTR | UCCUUCCCCUGCAACCA |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 20371350 / GSE21578 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
37 hsa-miR-1231 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT075228 | PHF13 | PHD finger protein 13 | 2 | 6 | ||||||||
MIRT266936 | HDGF | heparin binding growth factor | 2 | 6 | ||||||||
MIRT441394 | SOX5 | SRY-box 5 | 2 | 2 | ||||||||
MIRT446329 | ATP5C1 | ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 | 2 | 2 | ||||||||
MIRT446438 | THYN1 | thymocyte nuclear protein 1 | 2 | 2 | ||||||||
MIRT482781 | STIM1 | stromal interaction molecule 1 | 2 | 2 | ||||||||
MIRT497714 | CYP1A1 | cytochrome P450 family 1 subfamily A member 1 | 2 | 2 | ||||||||
MIRT500907 | STARD13 | StAR related lipid transfer domain containing 13 | 2 | 2 | ||||||||
MIRT503251 | KIF18B | kinesin family member 18B | 2 | 2 | ||||||||
MIRT504750 | TEP1 | telomerase associated protein 1 | 2 | 4 | ||||||||
MIRT512158 | CD164 | CD164 molecule | 2 | 6 | ||||||||
MIRT518043 | LSM3 | LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated | 2 | 4 | ||||||||
MIRT526038 | GMDS | GDP-mannose 4,6-dehydratase | 2 | 2 | ||||||||
MIRT529828 | ARGFX | arginine-fifty homeobox | 2 | 2 | ||||||||
MIRT531808 | POLD3 | DNA polymerase delta 3, accessory subunit | 2 | 2 | ||||||||
MIRT533139 | WNT10A | Wnt family member 10A | 2 | 2 | ||||||||
MIRT538612 | CCT5 | chaperonin containing TCP1 subunit 5 | 2 | 4 | ||||||||
MIRT555617 | PHLPP2 | PH domain and leucine rich repeat protein phosphatase 2 | 2 | 2 | ||||||||
MIRT561705 | PTP4A1 | protein tyrosine phosphatase type IVA, member 1 | 2 | 2 | ||||||||
MIRT562301 | GINM1 | glycoprotein integral membrane 1 | 2 | 2 | ||||||||
MIRT566732 | MSH6 | mutS homolog 6 | 2 | 2 | ||||||||
MIRT569369 | IMPG1 | interphotoreceptor matrix proteoglycan 1 | 2 | 2 | ||||||||
MIRT572314 | HSPB6 | heat shock protein family B (small) member 6 | 2 | 2 | ||||||||
MIRT574602 | LZIC | leucine zipper and CTNNBIP1 domain containing | 2 | 2 | ||||||||
MIRT612023 | FOXF2 | forkhead box F2 | 2 | 2 | ||||||||
MIRT616950 | MAPKAPK2 | mitogen-activated protein kinase-activated protein kinase 2 | 2 | 2 | ||||||||
MIRT624175 | DERL2 | derlin 2 | 2 | 2 | ||||||||
MIRT647634 | FAIM2 | Fas apoptotic inhibitory molecule 2 | 2 | 2 | ||||||||
MIRT659393 | CORO2A | coronin 2A | 2 | 2 | ||||||||
MIRT659955 | CXCL10 | C-X-C motif chemokine ligand 10 | 2 | 2 | ||||||||
MIRT684001 | FOLR1 | folate receptor 1 | 2 | 2 | ||||||||
MIRT688143 | GABPB1 | GA binding protein transcription factor beta subunit 1 | 2 | 2 | ||||||||
MIRT688609 | CYBRD1 | cytochrome b reductase 1 | 2 | 2 | ||||||||
MIRT693583 | SLC39A1 | solute carrier family 39 member 1 | 2 | 2 | ||||||||
MIRT699922 | RUFY2 | RUN and FYVE domain containing 2 | 2 | 2 | ||||||||
MIRT712961 | PET117 | PET117 homolog | 2 | 2 | ||||||||
MIRT723950 | TMEM184A | transmembrane protein 184A | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|